Skip to main content
. 2019 May 17;55(5):161. doi: 10.3390/medicina55050161

Figure 2.

Figure 2

Time course of (A) forced vital capacity (FVC), (B) serum fibrotic marker KL-6 and SP-D levels, and (C,D) serum periostin levels after administration of pirfenidone. After pirfenidone treatment, (A) FVC was improved, and (B) KL-6 and SP-D levels were normalized. Periostin levels were not clearly elevated on initial admission and were not affected by pirfenidone (C,D). Antibodies 18A X 17B (<95 ng/mL) and 20A X 19D (<13.4 ng/mL) recognize total (inflammatory and fibrotic) and monomeric (fibrotic) periostin, respectively [6].